Programs - ILS2024 | Innovation Leaders Summit

\ NOW ON STAGE /

Small molecules targeting the ANO1/EGFR complex for GBM and solid tumors

Novel PPI-based chemistry targets the ANO1/EGFR complex, a newly discovered glioblastoma biomarker, with additional indications in head and neck cancer and triple-negative breast cancer

Small molecules targeting the ANO1/EGFR complex for GBM and solid tumors

Novel PPI-based chemistry targets the ANO1/EGFR complex, a newly discovered glioblastoma biomarker, with additional indications in head and neck cancer and triple-negative breast cancer

Seonyoung Yang│Astrion Inc.,

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

Revolutionizing Obesity Treatment: Painless Microneedle Patches for Effective Drug Delivery

The MicroLock™ Patch offers a non-invasive alternative to traditional injections, enhancing patient compliance while providing sustained release of therapeutics. This innovation, particularly suited for chronic disease management, can significantly improve outcomes in the global fight against obesity by offering a convenient, patient-friendly, and effective drug delivery system.

Revolutionizing Obesity Treatment: Painless Microneedle Patches for Effective Drug Delivery

The MicroLock™ Patch offers a non-invasive alternative to traditional injections, enhancing patient compliance while providing sustained release of therapeutics. This innovation, particularly suited for chronic disease management, can significantly improve outcomes in the global fight against obesity by offering a convenient, patient-friendly, and effective drug delivery system.

Shayan Fakhraei Lahiji│Cursus Bio Inc.,

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

Development of Next-Generation Antifungal Drugs

Our company is focused on developing two major drug pipelines: a next-generation antifungal agent and a microbiome-based therapy for the treatment of Graves' disease. After securing seed funding, we are now seeking PreA investment to further our development efforts. The development of our next-generation antifungal agent has shown promising results at the laboratory level, with positive findings from activity tests, animal toxicity studies, and efficacy evaluations. We are now preparing to initiate non-clinical trials through a CRO. Upon completion of the non-clinical phase, we aim to enter preclinical studies in 2025. Simultaneously, we are advancing the development of our microbiome-based therapy using the NES-428 strain to treat Graves' disease. This strain has demonstrated effective results in animal studies, and we are currently investigating the mode of action of its therapeutic action.

Development of Next-Generation Antifungal Drugs

Our company is focused on developing two major drug pipelines: a next-generation antifungal agent and a microbiome-based therapy for the treatment of Graves' disease. After securing seed funding, we are now seeking PreA investment to further our development efforts. The development of our next-generation antifungal agent has shown promising results at the laboratory level, with positive findings from activity tests, animal toxicity studies, and efficacy evaluations. We are now preparing to initiate non-clinical trials through a CRO. Upon completion of the non-clinical phase, we aim to enter preclinical studies in 2025. Simultaneously, we are advancing the development of our microbiome-based therapy using the NES-428 strain to treat Graves' disease. This strain has demonstrated effective results in animal studies, and we are currently investigating the mode of action of its therapeutic action.

Cheolwon Yun│EsgelBio,

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

Photodynamic-Immuno Convergent Anticancer Therapy Using Immune Cell Differentiation Induction Technology

Cancer treatment has evolved through the development of first-generation cytotoxic chemotherapies, second-generation targeted therapies, and third-generation immunotherapies. Despite these advancements, cancer remains the leading cause of death worldwide due to intractable cancers. There is also a continual demand for technologies to prevent metastatic and recurrent cancers. MediArk has developed a photodynamic-immuno convergent anticancer therapy based on Metal-Organic Frameworks that applies localized photodynamic treatment and immune cell differentiation promotion techniques. This therapy has demonstrated excellent anticancer efficacy in both in vitro and in vivo evaluations. Notably, it has been shown to prevent 100% of cancer recurrences in recurrence trials. MediArk aims to commercialize this technology to ultimately treat intractable cancers that have not been previously conquered.

Photodynamic-Immuno Convergent Anticancer Therapy Using Immune Cell Differentiation Induction Technology

Cancer treatment has evolved through the development of first-generation cytotoxic chemotherapies, second-generation targeted therapies, and third-generation immunotherapies. Despite these advancements, cancer remains the leading cause of death worldwide due to intractable cancers. There is also a continual demand for technologies to prevent metastatic and recurrent cancers. MediArk has developed a photodynamic-immuno convergent anticancer therapy based on Metal-Organic Frameworks that applies localized photodynamic treatment and immune cell differentiation promotion techniques. This therapy has demonstrated excellent anticancer efficacy in both in vitro and in vivo evaluations. Notably, it has been shown to prevent 100% of cancer recurrences in recurrence trials. MediArk aims to commercialize this technology to ultimately treat intractable cancers that have not been previously conquered.

Se-na Kim│MediArk Inc.,

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

A specialist company focused on treating dry mouth

Rather than relying on traditional palliative medications, the goal of this treatment for dry mouth is to prevent age-related complications and ultimately extend lifespan.

A specialist company focused on treating dry mouth

Rather than relying on traditional palliative medications, the goal of this treatment for dry mouth is to prevent age-related complications and ultimately extend lifespan.

Jun Sangho│SiALBIO corp.,

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

Introduction of Cranebio femtech /at home rapid test products

Maintaining the current medical system will be challenging, and the era of medical delivery based on telemedicine will come soon. With the motto "Daily health examinations at home," we are developing 1. Feminine testers that enable women's daily health management with testers embedded into sanitary products; 2. DNA origami infection test kit with accuracy comparable to PCR testing.

Introduction of Cranebio femtech /at home rapid test products

Maintaining the current medical system will be challenging, and the era of medical delivery based on telemedicine will come soon. With the motto "Daily health examinations at home," we are developing 1. Feminine testers that enable women's daily health management with testers embedded into sanitary products; 2. DNA origami infection test kit with accuracy comparable to PCR testing.

Daisuke Yamamoto│Cranebio Co., Ltd.,

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

Development of a hybrid nanocoated stent for the lower extremity for the treatment of small diameter atherosclerotic lesions

When arteriosclerosis reduces blood flow to the lower limbs, it can cause pain, difficulty walking, and even tissue necrosis, potentially leading to leg amputation. Current stents only address the thigh area, with issues arising in smaller vessels below the knee due to foreign body reactions. Our company has developed a hybrid nanocoating stent to treat these unaddressed areas.

Development of a hybrid nanocoated stent for the lower extremity for the treatment of small diameter atherosclerotic lesions

When arteriosclerosis reduces blood flow to the lower limbs, it can cause pain, difficulty walking, and even tissue necrosis, potentially leading to leg amputation. Current stents only address the thigh area, with issues arising in smaller vessels below the knee due to foreign body reactions. Our company has developed a hybrid nanocoating stent to treat these unaddressed areas.

KENTA BITO│Global Vascular Co., Ltd., Presidend & CEO

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

\ NOW ON STAGE /

Next-Generation Real-Time Monitoring Driven by Fundamental Research in Voice Data

This research aims to develop next-generation real-time monitoring technology based on fundamental research in voice data. By leveraging audio feature extraction and machine learning, we can predict changes in heart rate and emotions in real-time, contributing to the prevention of drowsy driving and improving safety in work environments. The new algorithms, grounded in fundamental research, hold great potential for applications across various industries.

Next-Generation Real-Time Monitoring Driven by Fundamental Research in Voice Data

This research aims to develop next-generation real-time monitoring technology based on fundamental research in voice data. By leveraging audio feature extraction and machine learning, we can predict changes in heart rate and emotions in real-time, contributing to the prevention of drowsy driving and improving safety in work environments. The new algorithms, grounded in fundamental research, hold great potential for applications across various industries.

Kanji Okazaki│RimTech (Risk Measurement Technologies Co., Ltd. ), CEO

Life Sciences / Drug Discovery / Medical Devices / Regenerative Medicine

ILS2024 Time Table